radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to
Three main disorders that afflict the lungs are pulmonary fibrosis, cystic fibrosis, and lung cancer. Examine each of these in detail, identifying the terminology associated with their causes and diagnoses outlined in a table of terms. Pulmonary Fibrosis This lesson is going to define and briefly...
Non-small cell lung cancerImmunotherapyToxicityLIPIPredictorSurvivalBackground Immune checkpoint inhibitors (ICIs) have been proposed as the standard first-line and subsequent treatment for metastatic non-small cell lung cancer (NSCLC). This study analyzed whether patients with good lung immune prognostic...
Present address: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Authors and Affiliations Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea Byoung Chul Cho Se...
Non-small-cell lung cancer ORR: Objective response rate OS: Overall survival PCA: Principal components analysis PD: Progression of disease PD-1: Programmed cell death-1 PD-L1: Programmed cell death ligand-1 PFS: Progression-free survival PR: Partial response RECIST: Response Evaluati...
Lung Cancer: Targets and Therapy 1 September 2014 Number of times this article has been viewed Sacha I Rothschild Department of Internal Medicine, Medical Oncology, University Hospital Basel, Basel, Switzerland Abstract: The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. Th...
Surgery is the standard care for patients with early-stage lung cancer, and stereotactic body radiation therapy is an option for those who are medically inoperable or refuse surgery. Medical developments in diagnostic and therapeutic strategies would prolong prognosis of patients with cancer. The number...
Immunochemotherapy is the first-line standard for extensive-stage small-cell lung cancer (ES-SCLC). Combining the regimen with anti-angiogenesis may improve efficacy. ETER701 was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial t
基于此,AME出版社挑选了近年来发表的肺癌诊疗领域有挑战的临床病例汇编成书——Case Reports in Lung Cancer(中文译名《肺癌病例报告》)。这些病例既包括肺癌脑膜转移的药物治疗、罕见突变如EGFR-RAD51的药物治疗以及罕见合并症如肿瘤相关脑降解的处理;也包括基于ctDNA监测的新型药物治疗策略,以及药物治疗带来的罕见并发...
In an ongoing, open-label, single-arm phase II study ( NCT02927301 ), 181 patients with untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathologi